Frontline therapy with early intensification and autologous stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non-Hodgkin's lymphoma patients: A prospective randomized GEMOH report

Acta Haematologica

Volumn 115, Issue 1-2, 2006, Pages 15-21

  Baldissera, R C ^a   Nucci, M ^c   Vigorito, A C ^d,e   Maiolino, A ^c   Simoes B P ^g   Lorand Metze, I ^d   Aranha, F J P ^d,e   Miranda, E C M ^d   Pagnano, K B B ^d   Ruiz, M A ^b   Moraes, A A J G ^f   De Souza, C A ^d  

^a Marilia Medical School   (Brazil)

^b Sao Jose do Rio Preto University School of Medicine   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e Hospital Vera Cruz Minas Gerais   (Brazil)

^f Campinas Oncology Center   (Brazil)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

International prognostic index, high risk; Non Hodgkin's lymphoma, aggressive; Stem cell transplantation, autologous; VACOP B regimen

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL RATE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 31144464437     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089460     Document Type: Article

References (21)

1. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, Mann R, Resnick GD, Barcos M, Gottlieb A: Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327: 1342-1349.
2. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-1006.
3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994.
4. Baldissera RC, Aranha JF, Oliveira GB, Vigorito AC, Eid KA, Miranda EC, De Souza CA: High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma. Braz J Med Biol Res 2002;35:49-57.
5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der LH, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545.
6. Laport GF, Williams SF: The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 1998;25:503-517.
7. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B: International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999;17:423-429.
8. Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996;14:534-542.
9. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045-1051.
10. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, Bosly A, Morel P, Nouvel C, Tilly H, Lederlin P, Sebban C, Briere J, Gaulard P, Reyes F: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030.
11. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Rizzoli V: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:2796-2802.
12. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, Coiffier B, Tilly H, Gabarre J, Guilmin F, Hermine O, Reyes F: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-2479.
13. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Muller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Koppler H, Parwaresch R, Pfreundschuh M, Havemann K: Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. J Clin Oncol 2002;20:4413-4419.
14. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, Falini B, Storti S, Meloni G, Rizzo M, Molinari AL, Lauria F, Moretti L, Lauta VM, Mazza P, Guardigni L, Pescarmona E, Pileri SA, Mandelli F, Tura S: Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003;21:1255-1262.
15. Reyes F, Lepage M, Morel P, Lederlin P, Coiffier B, Tilly H, Bosly A, Gabarre J, Brière J, Fillet G, Molina T, Gisselbrecht C: Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: update results of the randomized LNH93-3 study. Blood 1997;90(10 suppl 1):594a.
16. O'Reilly SE, Hoskins P, Klimo P, Connors JM: MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991;2(suppl 1):17-23.
17. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
18. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995;13:588-595.
19. Nademanee A, Schmidt GM, O'Donnell MR, Snyder DS, Parker PA, Stein A, Smith E, Lipsett JA, Sniecinski I, Margolin K: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992;80:1130-1134.
20. Milpied NJ, Deconinck E, Colombat P, Ifrah N, Berthou C, Gressin R, lamy T, Jaubert J, Casassus P, Le Maignan C, Maisonneuve H, Ramee JF, Lemevel A, Jardel H, Desablens B, Harousseau JL: Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation vs standard CHOP regimen for patients (≤60 yr) with no IPI high-risk intermediate or high grade lymphomas (NHL). Final analysis of a randomized trial by the GOELAMS. Blood 2002;100:180a.
21. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-1295.